Computational chemistry

Think Bioscience extends Seed Round to accelerate pocket-finding platform

Retrieved on:

Tuesday, May 7, 2024

Molecule, Protein, SAB, GV (company), Computational chemistry, Genentech, Research, Gold, Therapy, Senior, GTPase, Drug development, Growth, Protein tyrosine phosphatase, Pharmaceutical industry

BOULDER, Colo., May 7, 2024 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has announced a $6M Seed Expansion. Existing investors are joined by YK Bioventures, bringing total funding to $26M. The additional raise will accelerate the company's pipeline and expand their unique approach for finding new functional pockets on challenging targets.

Key Points:

BOULDER, Colo., May 7, 2024 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has announced a $6M Seed Expansion.
The additional raise will accelerate the company's pipeline and expand their unique approach for finding new functional pockets on challenging targets.
Gary Yeung, a managing partner at YK Bioventures, added, "We invested in Think Bioscience because of its transformational platform for new discoveries.
"We look forward to working even more closely with Wendy," said Dr. Jerome Fox, co-founder and CEO at Think Bioscience.

General Inception Launches Igniter Europe with the support of leading institutions and venture capital firms

Retrieved on:

Tuesday, April 30, 2024

PALO ALTO, Calif. and LYON, France, April 29, 2024 /PRNewswire-PRWeb/ -- General Inception announces the launch of Igniter Europe, focused on building innovative companies in the field of oncology, autoimmune and rare diseases, with novel therapeutics and disruptive technology platforms that enable accelerated drug development with data analytics solutions leveraging patients' data and clinical insights early on in the phase of drug development.

Key Points:

The company works closely with renowned researchers and institutions to facilitate the inception and acceleration of startups.
The team operates daily on both sides of the Atlantic to streamline the development of breakthrough solutions for the healthcare industry.
"Igniter Europe's approach in the field of company creation and expansion, in close collaboration with General Inception, is quite original.
"Our support is based on more than 15 years' experience with the team as deeptech venture capital investors and a shared conviction in the value of their mission.

DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative

Retrieved on:

Monday, April 29, 2024

As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.

Key Points:

As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science.
Inspired by recent advancements of large language models, DP aspires to develop a similar foundational model for the atomic domain.
Industrial Software for Drug Discovery, Battery Development and beyond
Advancing AI for Science, DP Technology has developed a suite of industry applications based on its large science models and advanced algorithms.
Sun Weijie, founder and CEO of DP Technology, stated, "The launch of large science models is our firm commitment to advancing scientific and industrial innovation.

Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

Retrieved on:

Tuesday, April 16, 2024

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.

Key Points:

SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities.
“Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion.
Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science.

Odyssey Therapeutics Announces Strategic Collaboration to Advance AI-Driven Small Molecule Drug Discovery

Retrieved on:

Thursday, April 4, 2024

Biotechnology, Health, Pharmaceutical, Technology, Artificial Intelligence, Odyssey, Johnson & Johnson, Drug discovery, Patient, Artificial intelligence, Computational chemistry, Therapy, Machine learning, Pharmaceutical industry

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.

Key Points:

Odyssey Therapeutics, Inc. , a biotechnology company pioneering next-generation precision medicines, announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and optimize small molecule medicines against select therapeutic targets.
The companies will combine their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry and drug discovery to unlock difficult-to-drug targets.
“We are excited about this collaboration to push the boundaries of the drug discovery and development process, using the latest advancements in AI and ML to find solutions for serious diseases,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics.
Odyssey will receive an upfront payment and is eligible for milestone payments and royalties.

X‑Chem Adds Chief Technology Officer to Bolster Its Digital Drug Discovery Strategy

Retrieved on:

Tuesday, April 2, 2024

Software, Research, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Other Science, Health, Machine learning, Informatics, Computational chemistry, Chem, Creativity, Drug discovery

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.

Key Points:

X-Chem, the leading provider of innovative solutions in early-stage drug discovery, today announced the addition of Dr. Erin Davis as chief technology officer.
Dr. Davis brings extensive experience in the areas of data strategy, informatics, computational chemistry and software solutions in drug discovery.
The addition of Dr. Davis to X-Chem’s executive team bolsters X-Chem’s strategy of leveraging its data generation platforms and deploying digitized drug discovery solutions to its clients.
“I am so excited to see Erin join the amazing team we have here at X-Chem,” said Karen Lackey, chief executive officer.

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy

Retrieved on:

Monday, April 1, 2024

Biotechnology, Pharmaceutical, Health, Oncology, Entrepreneurship, Drug discovery, Patient, NEK1, Biology, Computational chemistry, Harmonic, Therapy, Multimedia, Polypharmacology

Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Key Points:

Turbine, a company that is building the world’s first predictive simulation of patient biology, and Harmonic Discovery (Harmonic), a therapeutics company building an integrated computational and experimental platform for kinase drug discovery and targeted polypharmacology, have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.
This press release features multimedia.
View the full release here: https://www.businesswire.com/news/home/20240401176466/en/
“We believe that the dark kinase NEK1 holds great potential as a drug target for developing cancer therapies addressing important resistance challenges in the clinic,” said Daniel Veres, M.D., Ph.D., Chief Scientific Officer and Co-Founder of Turbine.
Harmonic will assume responsibilities for computational chemistry and medicinal chemistry activities, while Turbine will be responsible for in silico simulations and wet-lab validation of target biology, including the identification of both synergistic kinase co-targets to NEK1 and patient populations most likely to benefit from therapies.

Hokkaido University finds a new route to recyclable polymers from plants

Retrieved on:

Thursday, March 21, 2024

Environment, Assistant, Recycling, Polymer, Research, ACS Macro Letters, Artificial intelligence, Hokkaido University, Plant, LGO, Computational chemistry, Plastic, Biomass

SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials. This is a key requirement to reduce the burden of plastic pollution in the environment. They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled. The method was published in the journal ACS Macro Letters.

Key Points:

Cellulose, abundantly available from plant biomass, can be converted into molecules used to make a new class of recyclable polymers, to sustainably replace some plastics.
SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials.
They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled.
To make their new polymers, the Hokkaido team used two commercially available small molecules, levoglucosenone (LGO) and dihydrolevoglucosenone (Cyrene), which are made from cellulose.

Hokkaido University finds a new route to recyclable polymers from plants

Retrieved on:

Thursday, March 21, 2024

Environment, Assistant, Recycling, Polymer, Research, ACS Macro Letters, Artificial intelligence, Hokkaido University, Plant, LGO, Computational chemistry, Plastic, Biomass

SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials. This is a key requirement to reduce the burden of plastic pollution in the environment. They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled. The method was published in the journal ACS Macro Letters.

Key Points:

Cellulose, abundantly available from plant biomass, can be converted into molecules used to make a new class of recyclable polymers, to sustainably replace some plastics.
SAPPORO, Japan, March 21, 2024 /PRNewswire/ -- Researchers at Hokkaido University have taken a significant step forward in the drive to make recyclable yet stable plastics from plant materials.
They developed a convenient and versatile method to make a variety of polymers from chemicals derived from plant cellulose; crucially, these polymers can be fully recycled.
To make their new polymers, the Hokkaido team used two commercially available small molecules, levoglucosenone (LGO) and dihydrolevoglucosenone (Cyrene), which are made from cellulose.

Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji

Retrieved on:

Wednesday, February 14, 2024

Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.

Key Points:

Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
Hideyoshi Fuji has been appointed Representative Director of Iktos K.K., and Vice-President, Japan Business Development and Operations.
Hideyoshi, 42, spent 13 years at Astellas Pharma Inc. (2009-2021) as an expert in computational chemistry and chemoinformatics.
After his career with Astellas Pharma, Hideyoshi became an entrepreneur in 2022 and supported business development and marketing efforts in Japan for overseas software companies.